Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.60 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200987 | 0.86 | MAPK8 (0.60) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL8258606 | 0.84 | MAPK8 (0.55) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL17229232 | 0.82 | MAPK8 (0.56) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL4193535 | 0.81 | AAK1 (0.67) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL1487612 | 0.81 | MAPK8 (0.67) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL8321012 | 0.81 | MAPK8 (0.63) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL13753917 | 0.81 | MAPK8 (0.63) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL11924765 | 0.80 | AAK1 (0.68) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL8298203 | 0.80 | MAPK8 (0.66) | MAPK8MAPK9MAPK10MAP3K11NTRK1 | |
| SCHEMBL8254992 | 0.79 | AAK1 (0.55) | MAPK8MAPK9MAPK10MAP3K11NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| US-7612086-B2 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2004101565-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | MAPK8 25/4885MAPK9 1/4885MAPK10 12/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | MAPK8 25/4885MAPK9 1/4885MAPK10 12/4885 |
| US-20070142366-A1 | Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation | API5, MAP3K5, MAP3K7 | MAPK8 111/4885MAPK9 78/4885MAPK10 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.